期刊文献+

尿细胞角蛋白CYFRA 21-1浓度检测对膀胱移行细胞癌的诊断价值 被引量:3

The Diagnose Value of the CYFRA 21-1 in Urine in Bladder Transitional Cell Carcinoma
下载PDF
导出
摘要 目的探讨检测尿细胞角蛋白CYFRA 21-1在诊断膀胱移行细胞癌中的价值。方法检测膀胱移行细胞癌患者与膀胱良性病变患者及健康对照组尿CYFRA 21-1的值,比较各组间的差异。结果移行细胞组尿CYFRA21-1浓度显著高于良性病变组及健康对照组,差异有高度统计学意义(P<0.001);良性病变组与健康对照组比较,差异无统计学意义(P>0.05);在移行细胞癌组中转移患者与未转移患者比较,差异亦有高度统计学意义(P<0.01)。结论尿CYFRA 21-1检测对诊断膀胱癌及其转移有一定的临床价值。 Objective To approach the value of detecting CYFRA 21-1 in urine to diagnose transitional cell carcinoma of the bladder. Methods To compare the value of CYFRA21-1 in the patients with carcinoma of the bladder and the patients with urinary system benign lesion and the patients with healthiness. Results The result of bladder cancer was obviously higher than that in the other groups(P〈0.001); comparing the results of the urinary system benign lesion and the group with healthiness had no statistical significance (P〉0.05); comparing the results of metastasis and non-metastasis patients with bladder cancer had statistical significance (P〈0.01). Conclusion The value of the CYFRA21-1 in urine has important clinical significance in the diagnoses of bladder cancer and metastasis.
出处 《苏州大学学报(医学版)》 CAS 北大核心 2008年第4期620-621,共2页 Suzhou University Journal of Medical Science
关键词 肿瘤标志物 膀胱癌 tumor marker bladder cancer
  • 相关文献

参考文献5

  • 1Buccheri G, Torchio P, Ferrigno D. Clinical equivalence of two cytokeratin markers in non-small cell lung cancer. a study of tissue polypeptide antigen and cytokeratin 19 fragments[J]. Chest 2003, 124(2):622-632.
  • 2高云朝,王美琴,陆云,程伟,张学平,刘兴党,林祥通.血清肿瘤标志物的检测对肺癌患者的诊断价值[J].中华结核和呼吸杂志,2005,28(4):268-269. 被引量:32
  • 3王建英,程建新,王淑英,苏杏满.细胞角蛋白片段抗原21-1检测对卵巢癌诊断的价值[J].实用癌症杂志,2004,19(4):377-378. 被引量:4
  • 4Tammela J, Lele S. New modalities in detection of recurrent ovarian cancer[J]. Curr Opin Obstet Gynecol, 2004, 16(1):5-9.
  • 5Pariente JL, Bordenave L, Jacob F, et al. Analytical and prospective evaluation of urinary cytokeratin 19 fragment in bladder cancer[J]. J Urol,2000,163(4):1116- 1119.

二级参考文献13

  • 1Grmec S, Gasparovic V. Comparison of APACHE II,MEES and Glasgow Coma Scale in patients with nontraumatic coma for prediction of mortality.Critical Care, 2001, 5:19-23.
  • 2Schneider J,Philipp M,Velcovsky HG,et al.Pro-gastrin-releasing peptide (ProGRP),neuron specific enolase(NSE),carcinoembryonic antigen(CEA) and cytokeratin 19-fragments(CYFRA21-1)in patients with lung cancer in comparison to other lung diseases.Anticancer Res,2003,23:885-894.
  • 3Barradas PA,Cristovao MM,Costa AM,et al.Comparison of three serum (CYFRA21-1,NSE and CEA)in lung cancer:diagnosis efficacy,prognostic importance,value in chemotherapy monitoring and in early prediction of relapse.Chest,1998,114:250s-255s.
  • 4Nakayama M,Satoh H,Ishikawa H,et al.Cytokeratin 19 fragment in patients with nonmalignant respiratory diseases. Chest,2003,123:2001-2006.
  • 5Miedouge M,Rouzaud P,Salama G,et al.Evaluation of seven tumour markers in pleural fluid for the diagnosis of malignant effusions.Br J Cancer,1999,81:1059-1065.
  • 6Boher JM,Pujol JL,Grenier J,et al.Markow model and Markers of small cell lung cancer:assessing the influence of reversible serum NSE,CYFRA 21-1 and TPS levels on prognosis[J].Br J Cancer,1999,79(9/10):1419.
  • 7Nakata B,Chung YS,Kato Y,et al.Clinical significance of serum CYFRA 21-1 in gastric cancer[J].Br J Cancer,1996,73(12):1529.
  • 8Stieber P,Schmeller N.Clinical relevance of CYFRA 21-1,TPA-IRMA and TPA-LIA-mat in urinary bladder cancer[J].Anticance Res,1996,16(6B):3793.
  • 9Nasu K,Etoh Y,Yoshimatsu J,et al.Serum levels of cytokeratin 19 fragment in cervical cancer[J].Gynecol Obstet Invest,1996,42(4):267.
  • 10Rafael M,Nagler,Mira Barak,et al.Early Diagnosis and Treatment Monitoring Roles of Tumor Markers Cyfra21-1 and TPS in Oral Squamous Cell Carcinoma[J].Cancer,1999,85(5):1018.

共引文献33

同被引文献30

引证文献3

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部